福泰制药宣布Inaxaplin在特定AMKD患者群体中取得积极结果,第13周UACR显著降低42.7%

投资观察
Sep 22

路透社9月22日消息——福泰制药(Vertex Pharmaceuticals)今日发布重大公告,披露其在APOL1介导肾病(AMKD)额外患者群体中开展的2b期AMPLIFIED研究取得积极成果。与此同时,该公司2/3期AMPLITUDE试验的受试者招募工作亦已圆满收官。

详细数据显示,对于伴有中度蛋白尿的AMKD患者,Inaxaplin在治疗第13周时使尿白蛋白肌酐比(UACR)较基线下降了42.7%。而在合并2型糖尿病的AMKD患者群体中,该药物同样展现疗效,UACR在第13周时降低17.3%。两项研究队列均显示,Inaxaplin总体安全性和耐受性良好,未出现意外安全信号。

值得注意的是,这是福泰制药在这两个特定亚群中首次公布Inaxaplin的临床数据,进一步拓展了该药物在AMKD治疗领域的潜在应用范围。AMKD是一种由APOL1基因变异驱动的进行性肾脏疾病,严重影响患者生活质量。福泰制药正在积极推进该药物的临床开发项目,AMPLITUDE试验的招募完成为后续关键性疗效验证奠定了基础。

投资者对此消息反应积极,认为这标志着福泰制药在精准医疗领域针对遗传性肾脏疾病的布局又向前迈出了坚实一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10